Mymd Pharmaceuticals (NASDAQ:QCLS) Releases Earnings Results

Mymd Pharmaceuticals (NASDAQ:QCLS) released its earnings results on Wednesday. The company reported ($0.79) earnings per share (EPS) for the quarter, Zacks reports.

Mymd Pharmaceuticals Stock Performance

Shares of NASDAQ QCLS opened at $2.89 on Thursday. The company has a market capitalization of $12.05 million, a price-to-earnings ratio of -0.14 and a beta of 2.16. The business’s 50 day moving average price is $3.48. Mymd Pharmaceuticals has a 1-year low of $2.50 and a 1-year high of $10.79.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on QCLS shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a research report on Friday, August 7th. Wall Street Zen cut shares of Mymd Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Mymd Pharmaceuticals presently has an average rating of “Sell”.

Mymd Pharmaceuticals Company Profile

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.